


Integrated GI / HPB

GI MOTILITY

ELECTRICAL




BER: Basal electrical rhythm

Pacemaker: Interstitial cells of Cajal ↓ pylorus

MECHANICAL

Segmentation **Peristalsis**




Hunger

MMC

migratory motor complexes

House keeping mot



MOTILIN

↓ ⊕

Macrolides

prokinetic

- Stomach-4
- Duodenum-12** max
- Jejunum-11
- Ileum-8
- Cecum-2** min
- Sigmoid-6

REFLEX

Enterogastric

CCK, secretin, Peptide Y

Fat > protein > Carbs
Acidity
Osmolarity

Gastrocolic



sigmoid
Colon

contraction

babies (+)

Gastro-ileal




relaxation
of IC
valve

GI hormones

REGULATORY SUBSTANCE	SOURCE	ACTION	REGULATION	NOTES
Gastrin	G cells (Antrum, duodenum)	↑ gastric acid secretion ↑ gastric motility	↑ by stomach distention, amino acids, vagal stimulation via GRP ↓ by pH < 1.5	↑ by chronic PPI use, chronic atrophic gastritis, Zollinger Ellison syndrome <i>parietal cells</i>
Cholecystokinin <i>iCCK</i>	I cells (antrum, SI)	↑ pancreatic secretion <i>enzyme</i> ↑ gallbladder contraction ↓ gastric emptying ↑ sphincter of Oddi relaxation	↑ by fatty acids, amino acids	Acts on neural muscarinic pathways to cause pancreatic secretion
Secretin	S cells (duodenum)	↑ pancreatic HCO ₃ ⁻ secretion ↓ gastric acid secretion ↑ bile secretion	↑ by acid, fatty acids in lumen of duodenum	↑ HCO ₃ ⁻ neutralizes gastric acid in duodenum, allowing pancreatic enzymes to function
Somatostatin	D cells (pancreatic islets) <i>deteriorates</i>	↓ Gastric acid and pepsinogen secretion ↓ Pancreatic and small intestine fluid secretion ↓ Gallbladder contraction ↓ Insulin and glucagon release	↑ by acid ↓ by vagal stimulation	Octreotide is an analog used to treat acromegaly, carcinoid syndrome, VIPoma, and variceal bleeding S/e: Gallstones (<i>GB stones</i>)



GI hormones

Incretin



<p>Glucose-dependent insulinotropic peptide = gastric inhibitory peptide (GIP (GLP=GIP))</p> <p><i>incretin</i></p>	<p>K cells (duodenum, jejunum)</p> <p><i>K cells</i></p>	<p>Exocrine: ↓ gastric H⁺ secretion</p> <p>Endocrine: ↑ insulin release</p>	<p>↑ by fatty acids, amino acids, oral glucose</p>	<p>Oral glucose load ↑ insulin compared to IV equivalent due to GIP secretion</p>
<p>Vasoactive intestinal polypeptide</p>	<p>Parasympathetic ganglia in sphincters, gallbladder, small intestine</p>	<p>↑ intestinal water and electrolyte secretion</p> <p>↑ relaxation of intestinal smooth muscle and sphincters</p>	<p>↑ by distention and vagal stimulation ↓ by adrenergic input</p>	<p>VIPoma- <u>WDHA</u> Watery Diarrhea, Hypokalemia, Achlorhydria (WDHA syndrome)</p>
<p>Ghrelin</p>	<p>Stomach</p>	<p>↑ appetite ("ghrowlin' stomach")</p>	<p>↑ in fasting state + by food</p>	<p>↑ in Prader-Willi syndrome</p> <p>↓ after gastric bypass surgery</p>

GI hormones



Total volume: 7L/day
 Max- *stomach* — Brunner glands
 Most alkaline pH: *Duodenum* ~ 8 pH
 Most acidic pH: *Stomach* ~ 1.5 pH
 Max K concentration: *COLON*
 Max K amount: *saliva*

radioactive B12

1) oral + 1M vit B12 → >10% vit B12
↓ <10%
radioact urine

dietary def

vegans

2) B12 + IF → (N) → pernicious anemia


3) B12 + antibiotics → (N) → SIBO / BOAS
↓ <10%
strictures / DM

4) B12 + pancreatic enzymes → (N) → pancreatitis
↓ <10%

MUCOSAL - ILEUM

• CD / Tropical sprue /

D. latum



H-2 Blockers: Cimetidine, famotidine, nizatidine
Cimetidine: $CYP \ominus$ / gynecomastia / creat \uparrow levels

\ominus NSAIDs
 (: peptic ulcer)
 PGE1 - misoprostol
DOC: PPI

Antacids: "makes go"
 $Al\ OH + Mg\ OH$
 constipⁿ diarrhea
 $CaCO_3$: milk alkali sx

PPI: Omeprazole, lansoprazole, pantoprazole-DOC
 Hit and run eosinophilia
 S/E: C.difficile, AIN, pneumonia, B12 deficiency, Fracture risk
 Omeprazole: CYP2C19-Clopidogrel

Sucralfate, bismuth ulcer protective
 black stomach

Triple drug therapy:
CAP: Clarithromycin + Amoxicillin + PPI
Quadruple: + Bismuth

CONSTIPATION

Bulk forming: **Methylcellulose**

Osmotic: **Lactulose, PEG** → IBS-C

Hepatic encephalopathy Lactic acid - H⁺
NH₃ → NH₄⁺

Stimulant: **Senna, Bisacodyl**

Cl channel activator: **Lubiprostone**

Guanylate cyclase Agonist: **CFTR** +- **Linaclotide, Plecanatide**

5HT-4 agonist: **Prucalopride**

NHE3 inhibitor: **Tenapanor** Na⁺ - H⁺ exchanger → ↑ Na⁺ excr
↑ H₂O excr

Peripheral opioid inhibitor: For **post-op ileus**

Alvimopan, Naloxegol, Methylnaltrexone



melanos coli

DIARRRHEA

u Agonist: **Loperamide** IBS-D → x sweating / dry mouth

Diphenoxylate-atropine: misuse prevent

Enkephalinase inhibitor: **Racecodotril**

5HT3 antagonist: **Alosetron**

Irritable Bowel Syndrome: Rome IV Criteria

Does the patient have recurrent abdominal pain at least 1 d per week (on average) in the last 3 mo associated with two or more of the following?

- Onset of symptoms related to defecation
- Onset of symptoms associated with a change in frequency of stool
- Onset of symptoms associated with a change in form of stool

Yes

No

Were the above criteria fulfilled for the last 3 mo with symptom onset at least 6 mo prior?

No

Does not meet IBS diagnostic criteria. Consider an alternate diagnosis.

Yes

IBS diagnostic criteria met. What is the predominant stool form?

Diarrhea (Bristol type 5 or 6)

Constipation (Bristol type 1 or 2)

Mixed (Bristol type 1-2 and 5-6)

IBS-D

IBS-C

IBS-M

LOW FODMAP DIET

VOMITING / OBESITY

5 HT3 blocker: Ondansetron (shortest),
Palonosetron (longest, most potent)

DOC-Post-op/ Post-chemo, Post-RT, Pregnancy
s/e: Headache, QT prolong, Constipation
Cisplatin - early can be used

Morning sickness: Doxylamine + B6

Sea sickness: Meclizine

Motion sickness: Hyoscine

Mountain sickness: Acetazolamide
resp alkalosis

^{Q3}
NK1 / Substance P inhibitor: Aprepitant
late onset Cisplatin DOC


CB1 agonist: Dronabinol, Nabilone
s/e: red eyes / ↓ BP

D2 blockers :

Metoclopramide: ✓ BBB → EPS, ↑ PRL
(5HT4 +: Used in Gastroparesis)
nigrostriatal / tuberoinfund

Domperidone: ✗ BBB

ASCITES



MANAGEMENT:

MILD - USG \neq salt restricⁿ

MOD - C/F \neq (distension) Loop diuretic \rightarrow K⁺ sparing diuretic

SEVERE - (resp distress) High vol paracentesis + albumin infusions
 $\approx 2.5L$ 6-8g / L - fluid removed

Spontaneous bacterial peritonitis:

Ascitic WBC $> 250/mm^3$

MCC: GNB - E. coli
 DOC: Ceftriaxone / Cefotaxime

DIARRRHEA

ACUTE

<6HRS *Performed*

CHINESE FOOD: *B. cereus* - emetic

DAIRY: *S. aureus*

>6HRS

Travelers: *ETEC* - LT/ST - ↑cAMP

Rice water: *V. cholera*

SHELLFISH: *V. parahaemolyticus* - Kanagawa

Camping/malabsorption: *Giardia*

Acute RIF pain: *y. enterocolitica*

Antibiotics ++ *C. difficile*

BLOODY:

-Poultry and eggs: *Salmonella*

-Severe dehydration: *Shigella*

-GBS, Reiter syndrome: *Campylobacter*

-Uremia / Anemia: *EHEC* - HUS O157:H7

-Flask shaped ulcer: Amebic - *E. histolytica*

-Longitudinal ulcers: *Typhoid*


-Transverse ulcers: *TB*



$$\text{Stool osmotic gap} = 290 - 2 \times (\text{stool Na} + \text{stool K})$$

LOW <50:

- ZES *Gastrinoma*
- Carcinoid ↑↑SHF₃



HLA-DQ2/ DQ8

Alpha-Gliadin

Anti-TTG - Best

Marsh staging

Biopsy: Duodenum IDA / Short stature

Dermatitis herpetiformis

CHRONIC:

HIGH >50

osmotic

resolves upon fasting

Positive hydrogen breath test: *Lactose intolerance*

Stool fat >7% "greasy stools"

D-xylose - /N

D-xylose + /Abn



Fecal elastase

Rifaximin

Pancreatitis

Mucosal Biopsy

SIBO/BOHS



foamy m phages

CELIAL disease


intraepithelial T-lymphocytes

PAS+ (DR) Whipple's D Trypanema whipelli (TB) AFB (+)

no ↑ Tcell lymphoma

PAS CAN foamy articular neural whipped


R₂: B R O W - Barley / Rye / oat / wheat ✓ Rice / Maize




POLYPS

Non-neoplastic

① Hyperplastic




② Inflammatory



Rectal bleeding
mucus discharge


③ Hamartomatous



4yr old with rectal bleeding

JUVENILE POLYP

SMAD4




11yr old with intussusception


Petz-Jegher's Sx

STK11 * Ca pancreas

Neoplastic



Tubular



Villians


↑ r/o malign

MOST IMP - Size

serrations
upper

vs
sessile
serrated
adenoma


Cowden syndrome PTEN - trichilemmomas / B E T
Crickhite-Canada syndrome - non inherited Breast endometrioid
TSC - ectodermal
Bannyan-Ruvalcaba-Riley syndrome MR (+) polyps



Haggit

HNPCC

Adenoma-carcinoma sequence AK53



- Tumors associated with **BRAF mutation** are: **V600E**
- Melanoma
 - Adenocarcinoma of colon
 - Papillary thyroid carcinoma
 - Hairy cell leukemia
 - Langerhans cell histiocytosis
- BRAF inhibitors **Debrafenib, vemurafenib** have demonstrated efficacy in patients with lung cancer harboring BRAF mutations

Form linked to APC gene → FAP	Form linked to MUTYH gene → MAP
Surveillance should start at age 10-12 with annual colonoscopy every 1-2 years until the patient undergoes surgery	Endoscopic surveillance should start at age 20-25 with chromo-endoscopy every 1 to 2 years

Revised criteria (Amsterdam criteria II) **Mismatch**

At least **three relatives** with an **HNPCC-associated cancer** (colorectal cancer, cancer of endometrium, small bowel, ureter, or renal pelvis)

One should be a **first-degree** relative of the other two

At least **two successive generations** should be affected

At least one should be diagnosed before age **50 years**

AD, >100 polyps, earlier age
100% risk of ca colon
 Left colon MC
Gardner: *osteomas, seb cysts, fibromas, CHAPE*
Turcot: *MB / GBM*

AR, <100 polyps, later
Duodenal adenomas,
ovarian and bladder cancers



AD, 80% risk of ca colon
Right colon

1-2-3

R₀ - total proctocolectomy + IPAA

IBD


	Ulcerative colitis	Crohn's disease
Wall layer	superficial - mucosa	transmural
MC site	Rectum	terminal ileum
Stricture, Fistula, Abscess	(-)	++
Skip lesions	Continuum	skip lesions
Antibody	p-ANCA	ASCA S. cerevisiae
H/P	crypt abscess	NC granulomas
Earliest imaging finding	mucosal granularity	aphthous ulcers
Extra-intestinal manifestations	Rash (pyoderma gangrenosum, erythema nodosum), eye inflammation (episcleritis, uveitis), oral ulcerations (aphthous stomatitis), Peripheral arthritis, Ank spondylitis	
Management	<p>PSC</p> <p>sulfasalazine (5-ASA) → Steroids → Biologicals</p> <p>no ca colon ↑ UC (Sx) ←</p>	<p>Ca oxalate stones</p> <p>Steroids → Biologicals</p>
Fecal lactoferrin, Fecal calprotectin	<p>Smoking, Childhood appendectomy: protective (UC)</p> <p>↑ inflammation</p>	<p>resolve c f</p>




Lead pipe colon




Pseudopolyps



No granulomas




String
s/o Kantor



Comb sign




Cobblestoning
Creeping fat





Crypt
abscess

VC




CIRRHOSIS

Estrogen



CNF Nutmeg liver
 Centrilobular congestion
 + periportal sparing



Space of Disse:
 ITO Cells/ Stellate cells







vit A ↓ amyloid
 ↓ cirrhosis → bridging coll 1/3
fibrosis

HEPATIC ENCEPHALOPATHY
 EARLIEST SYMPTOM: Sleep-wake cycle
 SPECIFIC SIGN: Asterixis
 EEG: Triphasic
 Staging: West Haven
 Mx: Rifaximin + Lactulose

HPS + albumin
 Platypnea
 = Orthodeoxia

HRS terlipressin
 Pre-renal
 AKI
 FeNa <1%
 No s/o shock

HEPATITIS



SCOT ALCOHOLIC hepatitis

AST > ALT > 2:1, AST < 400
 Mallory Denk bodies
 CK 8/18
 Intermediate filaments
 Lille index*
 Macrovesicular steatosis

Viral hepatitis

ALT > AST **Hep C**
 Councilman bodies
 Portal tract expansion
 Macrovesicular steatosis

recurrent, young ♀

ANA, SMA: type 1
 LKM-1, SLA, LC: type 2
 AI hepatitis

Duct fluid lesions

Anti-mitochondrial Ab

Hep B:

Ground glass hepatocytes, Orcein Shikata stain

Maddrey's DF - steroids

$$DF = (4.6 \times [\text{prothrombin time (sec)} - \text{control prothrombin time (sec)}]) + (\text{serum bilirubin})$$

	Non-severe Disease	Severe Disease
MDF score	< 32	> 32
Short-term mortality	10 %	30-60%
Corticosteroids?	No	Yes


NASH: Vit E approved
 Metformin
 Liraglutide
 Pioglitazone PPAR γ (+)
 Saroglitazor PPAR $\alpha + \gamma$ (+)
 Lanifibranor Pan PPAR (+)

Pruritus
 osteopenia
 xanthelasma


↑ Ca colon
 h/o VC
 on sun skin

PBC → ↑CCA pre-malignant → **PSC**
 "beaded" LMRCF

LIVER DISEASES




WILSON D




Perris / Prussian blue



Hemochromatosis



PAS + DR



dense bodies

aggregates of misfolded prtn

α_1 AT def

Panlobular emphysema + (LL)

Cirrhosis

Co-dominant



ATP 7B-Chr 13
 Ceruloplasmin: \downarrow
 Urine copper: \uparrow
 Type 2 RTA
 KF rings- Cu - DM
 Neuro- 90%
 Hepatic- 50%
 TOC: Zn / D-penicillamine
 With hepatic decompensation- Trientine

HFE-Chr 6
 Hepcidin DM
 Liver, Pancreas, Pituitary, Skin Bronze
RCM/ DCM
 Hook shaped metacarpals
 Pseudogout

$R_p \rightarrow$ Fe chelating / Phlebotomy

Cu stains: Rhodamine
 Rubeanic acid

Viral hepatitis

Risk of chronic Hepatitis:

HBV: 1-90% \rightarrow \oplus HBeAg \ominus

HCV: 85%

Hep A/HepE: 0% (Feco-oral)


MC acute hepatitis: Hep E \rightarrow pregn - 20% mortality

MANAGEMENT:

HBV DNA >2000IU/ml:

Tenofovir / Entecavir / IFN a

12 wks



NS3/4A Protease Inhibitors

Telaprevir
Boceprevir
Simeprevir
Faldaprevir
Vaniprevir
Asunaprevir

NS5A Replication Complex Inhibitors

Daclatasvir
Ledipasvir
MK-8742
Velpatasvir

NS5B Polymerase Inhibitors

Nucleoside Inhibitor

Sofosbuvir

+

Non-Nucleoside Inhibitors

Deleobuvir

BMS-791325

x 12 wks

DAAs (HCV-Specific)



DAAs (HCV-Non-Specific): (Peg)interferon, Ribavirin

HBsAg <i>Infn</i>	Anti-HBs <i>immunity</i>	Anti-HBc	HBeAg <i>(↑ Infn)</i>	Anti-HBe <i>(↓ Infn)</i>	Anti-HDV	Anti-HCV	HCV RNA	Anti-HEV	
+	-	IgM	+	-	-	-	-	-	Acute Hep B - ↑ Infn
+	-	IgG	+	-	-	-	-	-	Chr Hep B - ↑ Infn
+	-	IgG	-	+	-	-	-	-	✓ ALT normal ✓ HBV DNA <2000 Inactive carrier
+	-	IgG	-	+	-	-	-	-	ALT raised HBV DNA >2000 Precore mutant
+	-	IgM	+	-	+	-	-	-	Acute Hep B + D Co-Infn
+	-	IgG	+	-	+	-	-	∴	Chr Hep B + D Super Infn
-	-	IgM	+	-	-	-	-	-	Window period
-	+	IgG	-	+	-	-	-	-	Recovered
-	-	IgG	-	+/-	-	-	-	-	Remote past ^{or}
-	+	-	-	-	-	-	-	-	Vaccinated
-	-	-	-	-	-	+	-	-	Recovered Hep C
-	-	-	-	-	-	+	+	-	Infn - Hep C